Functional Characterization of the Protease of Human Endogenous Retrovirus, K10:  Can It Complement HIV-1 Protease?

To investigate the biochemical properties of the protease encoded by the human endogenous retrovirus, K10 (HERV-K), 213 amino acids of the 3‘-end of the HERV-K protease (PR) open reading frame were expressed in Escherichia coli. Autocatalytic cleavage of the expressed polypeptide resulted in an 18.2...

Full description

Saved in:
Bibliographic Details
Published in:Biochemistry (Easton) Vol. 37; no. 49; pp. 17137 - 17144
Main Authors: Towler, Eric M, Gulnik, Sergei V, Bhat, T. N, Xie, Dong, Gustschina, Elena, Sumpter, Terry R, Robertson, Nicole, Jones, Christopher, Sauter, Marlies, Mueller-Lantzsch, Nikolaus, Debouck, Christine, Erickson, John W
Format: Journal Article
Language:English
Published: United States American Chemical Society 08-12-1998
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the biochemical properties of the protease encoded by the human endogenous retrovirus, K10 (HERV-K), 213 amino acids of the 3‘-end of the HERV-K protease (PR) open reading frame were expressed in Escherichia coli. Autocatalytic cleavage of the expressed polypeptide resulted in an 18.2 kDa protein which was shown to be proteolytically active against a fluorogenic peptide used as a substrate for HIV-1 protease. On the basis of sequence homology and molecular modeling, the 106 N-terminal amino acids of HERV-K PR were predicted to comprise a retroviral protease core domain. An 11.6 kDa protein corresponding to this region was expressed and shown to be a fully functional enzyme. The 11.6 kDa domain of HERV-K PR is unusually stable over a wide pH range, exhibits optimal catalytic activity between pH 4.0 and 5.0, and exists as a dimer at pH 7.0 with a K d of 50 μM. Like HIV-1 PR, the HERV-K PR core domain is activated by high salt concentrations and processes HIV-1 matrix-capsid polyprotein at the authentic HIV-1 PR recognition site. However, both the 18.2 and 11.6 kDa forms of HERV-K PR were highly resistant to a number of clinically useful HIV-1 PR inhibitors, including ritonavir, indinavir, and saquinavir. This raises the possibility that HERV-K PR may complement HIV-1 PR during infection, and could have implications for protease inhibitor therapy and drug resistance.
Bibliography:istex:6919FFC33496324EE68CF8061CC240709BD1BC79
ark:/67375/TPS-GSLN0WVD-T
Supported in part by NIH Grant R01 GM50579.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0006-2960
1520-4995
DOI:10.1021/bi9818927